WBB Securities reiterated their buy rating on shares of Omeros Corporation (NASDAQ:OMER) in a report published on Monday. They currently have a $75.00 price target on the biopharmaceutical company’s stock.

OMER has been the topic of several other reports. Cantor Fitzgerald reaffirmed a buy rating and issued a $21.00 price objective on shares of Omeros Corporation in a report on Wednesday, August 10th. Maxim Group dropped their price objective on shares of Omeros Corporation from $30.00 to $19.00 and set a buy rating on the stock in a report on Wednesday, August 10th. Wedbush reaffirmed an outperform rating and issued a $56.00 price objective (down from $62.00) on shares of Omeros Corporation in a report on Thursday, August 11th. Zacks Investment Research downgraded shares of Omeros Corporation from a hold rating to a sell rating in a report on Wednesday, July 13th. Finally, FBR & Co reaffirmed an outperform rating and issued a $38.00 price objective on shares of Omeros Corporation in a report on Wednesday, June 29th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company has an average rating of Buy and an average price target of $32.45.

Shares of Omeros Corporation (NASDAQ:OMER) traded down 1.645% during mid-day trading on Monday, reaching $7.475. 158,801 shares of the company’s stock were exchanged. The stock’s market capitalization is $293.72 million. The company’s 50 day moving average is $10.51 and its 200 day moving average is $11.63. Omeros Corporation has a 1-year low of $7.26 and a 1-year high of $16.80.

Omeros Corporation (NASDAQ:OMER) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.18. The company had revenue of $10 million for the quarter, compared to analysts’ expectations of $9.80 million. The firm’s revenue for the quarter was up 212.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.44) EPS. Equities research analysts anticipate that Omeros Corporation will post ($1.55) EPS for the current fiscal year.

In other Omeros Corporation news, VP Marcia S. Kelbon sold 16,000 shares of the company’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total transaction of $174,560.00. Following the completion of the transaction, the vice president now directly owns 179,597 shares in the company, valued at $1,959,403.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Marcia S. Kelbon sold 15,900 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $11.56, for a total transaction of $183,804.00. Following the transaction, the vice president now owns 179,497 shares of the company’s stock, valued at $2,074,985.32. The disclosure for this sale can be found here. Company insiders own 13.60% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the company. Ingalls & Snyder LLC bought a new position in Omeros Corporation during the second quarter worth $46,441,000. Bank of Montreal Can bought a new position in Omeros Corporation during the second quarter worth $17,641,000. State Street Corp boosted its position in Omeros Corporation by 16.8% in the second quarter. State Street Corp now owns 881,993 shares of the biopharmaceutical company’s stock worth $9,274,000 after buying an additional 126,595 shares in the last quarter. Chicago Equity Partners LLC bought a new position in Omeros Corporation during the second quarter worth $961,000. Finally, GSA Capital Partners LLP bought a new position in Omeros Corporation during the second quarter worth $762,000. Institutional investors own 48.04% of the company’s stock.

About Omeros Corporation

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.